Tailored Treatment in Metastatic Colorectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00396487|
Recruitment Status : Terminated (Only one patient included as per Feb. 4, 2008.)
First Posted : November 7, 2006
Last Update Posted : June 11, 2015
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Colorectal Cancer||Drug: Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat||Phase 3|
The TS and MTHFR polymorphism has been investigated in a new study based on analysis of normal tissue. The results indicated that protein with a 3/3 TS polymorphism or a MTHFR T polymorphism had a significantly higher response rate and a longer time to progression than the other groups when treated with bolus 5-FU.
Capecitabine is metabolised to 5-FU through a number of enzymatic steps. It is the first rationally designed drug that is based upon the high concentration of thymidine phosphorylase (TP) in many human tumors compared to normal tissue. TP is the last step in the conversion of capecitabine to 5-FU and seems to be the limiting factor for the activation. Capecitabine may to some extent mimic continues 5-FU infusion as opposed to bolus 5-FU. A number of small investigations have indicated that patients with 2R/2R TS polymorphism have a higher response rate than heterozygous patients.
The TS and MTHFR polymorphism analysis can easily be performed on sputum, which means an easy collection and sending of the samples.
At present single agent chemotherapy is based on three drugs (5-FU, capecitabine, and Irinotecan) with almost the same overall activity. It seems rational to investigate if improvement can be obtained by tailoring the treatment according to gene polymorphism.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Tailored Treatment of Metastatic Colorectal Cancer Based on Genetic Markers|
|Study Start Date :||November 2006|
|Actual Study Completion Date :||February 2008|
- The primary end point is
- Response according to RECIST criteria.
- Secondary end points are
- Progression free survival
- Overall survival
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00396487
|Aalborg, Denmark, 9100|
|Aarhus University Hospital|
|Aarhus, Denmark, 8000|
|Copenhagen, Denmark, 2100|
|Sydvestjysk Hospital Esbjerg|
|Esbjerg, Denmark, 6700|
|Herlev, Denmark, 2730|
|Herning Central Hospital|
|Herning, Denmark, 7400|
|Næstved, Denmark, 4700|
|Odense University Hospital|
|Odense, Denmark, 5000|
|Roskilde, Denmark, 4000|
|Viborg, Denmark, 8800|
|Principal Investigator:||Anders Jakobsen, Prof, MDSc||Department of Oncology, Vejle Hospital, 7100 Vejle, DK-Denmark|